Tech Company Financing Transactions
GlyGenix Therapeutics Funding Round
On 3/18/2014, GlyGenix Therapeutics announced $150 thousand in Seed financing from Connecticut Innovations.
Transaction Overview
Company Name
Announced On
3/18/2014
Transaction Type
Venture Equity
Amount
$150,000
Round
Seed
Investors
Proceeds Purpose
The company will use the funds to continue research and development on its lead drug candidate, AAV-G6Pase, for the treatment of glycogen storage disease type 1a (GSD1a).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
15 Research Dr.
Woodbridge, CT 06525
USA
Woodbridge, CT 06525
USA
Phone
Website
Email Address
Overview
GlyGenix Therapeutics, Inc. develops therapeutic products for the treatment of cure metabolic disorders. The company manufactures and
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Fodor
Chief Financial Officer
Ramesh Ratan
Chief Operating Officer
David Feldman
Browse more venture capital transactions:
Prev: 3/18/2014: Bitvore venture capital transaction
Next: 3/18/2014: Flite venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs